INTRODUCTION
Hallmark pathologies of Alzheimer's disease (AD) are extracellular senile plaques consisting of aggregated amyloid b peptide (Ab) and intraneuronal neurofibrillary tangles (NFTs) composed of pathological tau fibrils, while similar tau lesions in neurons and glia are also characteristic of other neurodegenerative disorders, such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) , that are collectively referred to as tauopathies (Ballatore et al., 2007) . The discovery of tau gene mutations in a familial form of tauopathy, known as frontotemporal dementia and parkinsonism linked to chromosome 17 , and subsequent studies of transgenic (Tg) mice expressing human tau with or without these mutations, clearly implicate pathological tau in mechanisms of neurodegeneration in AD and related tauopathies (Ballatore et al., 2007) . Thus, there is an urgent need for tau imaging techniques to complement Ab amyloid imaging methods that now are widely used.
In vivo imaging modalities, as exemplified by positron emission tomography (PET) (Klunk et al., 2004; Small et al., 2006; Kudo et al., 2007; Maeda et al., 2007) , optical scanning (Bacskai et al., 2003; Hintersteiner et al., 2005) , and magnetic resonance imaging (MRI) (Higuchi et al., 2005) , have enabled visualization of Ab deposits in humans with AD and/or AD mouse models, and there has been a growing expectation that low-molecular-weight ligands for b-pleated sheet structures will also serve as molecular probes for tau amyloids. Although the majority of plaqueimaging agents used for clinical PET studies do not bind to tau lesions , at least one radiolabeled b sheet ligand, [ 18 F]FDDNP, enables PET imaging of AD NFTs (Small et al., 2006) . However, a relatively low contrast of in vitro autoradiographic and in vivo PET signals for [ 18 F]FDDNP putatively reflecting tau lesions does not allow a simple visual inspection of images for the assessment of tau pathologies in living subjects (Small et al., 2006; Thompson et al., 2009 (Klunk et al., 2004) and United States Food and Drug Administrationapproved [ 18 F]florbetapir (Yang et al., 2012) . In addition, [ 18 F]FDDNP and several other candidate tau probes do not bind to tau inclusions in non-AD tauopathy brains without plaque deposition (Okamura et al., 2005) and therefore can be clinically characterized only in AD patients with comingled Ab and tau amyloids. Hence, compounds that detect diverse tau aggregates, including tau inclusions in non-AD neurodegenerative diseases and tau Tg models, could be used to interrogate in vivo interactions between exogenous ligands and tau pathologies.
Here, we found that the lipophilicity of b sheet ligands is associated with their selectivity for tau versus Ab fibrils and that the core dimensions of these chemicals are major determinants of their reactivity with a broad spectrum of tau aggregates in diverse tauopathies and mouse models of tau pathology. Building on these observations, we developed a series of fluorescent compounds capable of detecting diverse tau lesions using optical and PET imaging in living Tg mouse models of tauopathies. Finally, we identified a radiotracer that produced the highest contrast for tau inclusions in animal PET and used it in exploratory in vivo imaging studies of AD patients, providing clear demonstration of signal intensification in tau-rich regions, in sharp distinction to [ 11 C]PIB-PET data reflecting plaque deposition.
RESULTS

Identification of PBBs as Ligands for Diverse Tau Inclusions in Human Tauopathies
We screened an array of fluorescent chemicals capable of binding to b sheet conformations (see the Compounds subsection in the Experimental Procedures). Fluorescence labeling with these compounds were examined in sections of AD brains bearing Ab and tau amyloids (Figures 1A and 2A) and non-AD tauopathy brains characterized by tau inclusions and few or no Ab plaques ( Figure 2 ). Amyloid PET tracers currently used for human PET studies, PIB (Klunk et al., 2004) , and BF-227 (Kudo et al., 2007) , tightly bound to senile plaques, while they only weakly reacted with AD NFTs (Figures 1A; Figure S1 available online). PET probes reported to selectively label tau aggregates, BF-158 (Okamura et al., 2005) and THK523 (Fodero-Tavoletti et al., 2011) , detected AD NFTs (Figures 2A and S1 ) but microscopically detectable fluorescence signals produced by FDDNP, which are presumed to bind to both Ab and tau fibrils (Small et al., 2006) , were consistent with dense cores of classic plaques and distinct from tau lesions (Figures 2A and S1 ). None of the above-mentioned PET ligands were reactive with tau inclusions in non-AD tauopathies, such as Pick bodies in Pick's disease (Figures 2A and S1 ) and neuronal and glial fibrillary lesions in PSP and CBD (data not shown). By contrast, these pathologies were intensely labeled with a widely used amyloid dye, thioflavin-S, and a derivative of another classic amyloid dye Congo red, (E,E)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (FSB) (Higuchi et al., 2005; Maeda et al., 2007) (Figures 1, 2A , and S1), although these chemicals may not undergo efficient transfer through the blood-brain barrier (BBB) (Zhuang et al., 2001) . Because compounds possessing a p-electron-conjugated backbone longer than 13Å exhibited affinities for pathological inclusions in a broad range of tauopathies, we examined binding of additional chemicals with a variety of structural dimensions to tau aggregates and found that affinity for non-AD tau inclusions could be attributed to a core structure with a specific extent ranging from 13 to 19 Å (Figure S1 ). Based on this view and the known fact that chemicals with a flat and slender backbone could pass through and attach to channel-like accesses in b-pleated sheets (Krebs et al., 2005) , we developed a class of compounds, phenyl/pyridinylbutadienyl-benzothiazoles/benzothiazoliums (PBBs), by stretching the core structure of a prototypical fluorescent amyloid dye, thioflavin-T, with two C = C double bond inserts between aniline (or aminopyridine) and benzothiazole (or benzothiazolium) groups ( Figure 1B ).
All PBB compounds intensely labeled NFTs, neuropil threads, and plaque neurites in AD brains ( Figure 1C) . Interestingly, the affinity of these PBBs for Ab plaques lacking dense cores was positively correlated with their lipophilicity ( Figure 1C ), and thereby three potential probes with relatively low logP (log of the octanol/water partition coefficient) values, including PBB3, 2-[4-(4-methylaminophenyl)-1,3-butadienyl]-benzothiazol-5,6-diol (PBB4) and PBB5 (structurally identical to Styryl 7, CAS registry number 114720-33-1), appeared suitable for visualizing tau pathologies in living organisms with reasonable selectivity. High-affinity of PBBs for tau lesions was further demonstrated by fluorometric analyses using Ab and tau filaments assembled in a test tube (Table S1 ; experimental procedures are given in the Supplemental Experimental Procedures), but the most and least lipophilic PBB members displayed similar selectivity for in vitro tau versus Ab pathologies, implying a methodological limitation in screening chemicals for tauselective ligands based on binding to synthetic peptides and recombinant proteins. PBBs and FSB were also shown to label tau inclusions in non-AD tauopathies, such as Pick's disease (Figures 2A and S1 ), PSP, and CBD ( Figure 2B ), all of which were immunodetected by an antibody specific for phosphorylated tau proteins (AT8).
In Vitro and Ex Vivo Fluorescence Imaging of Tau Lesions in Tau Tg Mice by PBBs
To obtain in vivo evidence of direct interaction between PBBs and tau lesions, we employed Tg mice expressing a single human four-repeat tau isoform with the P301S FTDP-17 mutation (PS19 line, see Figure S2 for neuropathological features of this Tg strain) (Yoshiyama et al., 2007) . Similar to the findings in non-AD tauopathy brains, NFT-like inclusions in the brain stem and spinal cord of PS19 mice were clearly recognized by PBBs ( Figures 3A and S1 ). We then performed ex vivo fluorescence labeling of tau lesions in PS19 mice with intravenously administered PBBs. Brains and spinal cords were removed 60 min after tracer injection, and fluorescence microscopy revealed an intense accumulation of these compounds in fibrillary tau inclusions abundantly seen throughout the sections by staining with thioflavin-S, FSB, and AT8 ( Figure 3B ). On the other hand, no overt in vitro ( Figure 3A ) or ex vivo (data not shown) fluorescence of these ligands was noted in the corresponding regions of non-Tg wild-type (WT) mice. Consistent with these observations, two-photon laser scanning fluorescence microscopy of ex vivo samples demonstrated somatic and neuritic staining of a subset of tangle-bearing neurons with intravenously injected 2-[4-(4-methylaminophenyl)-1,3-butadienyl]-benzothiazol-6-ol (PBB2) and PBB4 in unsliced spinal cord blocks from PS19 mice ( Figure 3B ).
In Vivo Macroscopic and Mesoscopic Optical Detection of Fibrillar Tau Pathologies in a Mouse Model Using PBB5
We next characterized PBBs with the use of in vivo fluorescence imaging modalities, which permitted a quick assessment of Following fluorescence labeling (pseudocolors are converted to green) with PIB (top row) and FSB (middle row), the samples were immunostained with an antibody against AbN3(pE) (red in the right column). PIB intensely labeled Ab plaques (white arrowheads) but did not clearly label NFTs (arrows). By contrast, NFTs and neuropil threads were intensely labeled by FSB, whereas the staining of diffuse plaques was negligible. A section was also doubly immunolabeled (bottom row) with AT8 (green) and anti-AbN3(pE) antibodies (red in the right panel), to demonstrate the abundance of tau and Ab amyloids in this area. Yellow arrowheads indicate tau-positive dystrophic neurites associated with senile plaques. (B) Structures of PBBs. Neutral benzothiazoles (PBB1-4) are newly synthesized chemicals, and a charged benzothiazolium, PBB5, is identical to a commercially available near-infrared laser dye. (C) Confocal fluorescence images of PBBs (pseudocolors are converted to green) and AbN3(pE) (red in the right column) staining in sections adjacent to those displayed in (A). The intensity of plaque staining (arrowheads) relative to that of NFTs (arrows) was positively associated with the lipophilicity of PBBs. As compared with PBB1 (top row) staining, labeling of diffuse plaques with PBB3 (middle row) was substantially attenuated. PBB5 was nearly unreactive with diffuse plaques (bottom row), and subsequent double immunofluorescence staining of the same section (bottom row in C) illustrated good agreement of PBB5 labeling with the distribution of AT8-positive NFTs. Scale bar, 50 mm (A and C). See also Figure S1 and Table S1. candidate chemicals without the need for radiolabeling. Because PBB5 is fluorescent, with peak excitation and emission wavelengths in a near-infrared range (Table S1 ), this compound is applicable to in vivo optical imaging of tau deposits in laboratory animals. To examine this possibility, fluorescence images were obtained from living mice over a time course following intravenous PBB5 injections using a small animal-dedicated system permitting the intravital observation of fluorescence signals at magnifications varying between macroscopic and microscopic levels. Tail vein administration of PBB5 in PS19 mice revealed strong fluorescence relative to non-Tg WT mice in the central nervous system (CNS) above the slit between the base of the skull and first vertebra, through the skin and connective tissues overlaying the cisterna magna ( Figures S3A-S3D) , suggesting a concentration of this tracer in the PS19 spinal cord. In line with this in vivo observation, the hindbrain and spinal cord of PS19 mice, which were dissected out at 2 hr after the injection of PBB5, exhibited increased retention of this compound compared to non-Tg WT mice ( Figures S3E-S3G) .
In vivo optical imaging of tau Tg mice was subsequently performed using a device equipped with a pulsed diode laser and a photomultiplier tube to detect deep signals through the skull. Elevated levels of fluorescence intensity were found in homogenized brain stem samples collected from PS19 mice at 20 hr after the intravenous tracer administration ( Figure S4A ), indicating a long-lasting in vivo binding of PBB5 to tau fibrils. To support the ex vivo evidence, fluorescence intensity was noninvasively analyzed in living PS19 and non-Tg WT mice treated with PBB5. The mice, with their heads shaved in advance, were prescanned, and autofluorescence signals were detected at a relatively high level in an area corresponding to the frontal forebrain. Using these baseline signals as landmarks, regions of interest (ROIs) were defined in the frontal cortex, brain stem, and spinal cord ( Figure 4A ). The near-infrared fluorescence was notably increased immediately after the intravenous injection of PBB5 ( Figure S4C ), and the fluorescence in the brain stem and spinal cord ROIs of PS19 mice much exceeded that in WT mice at 30 min ( Figure 4B ). Fluorescence intensity in the frontal cortex ROI, normalized on the basis of integration time and laser power, was lower in PS19 mice than in WT mice over 120 min after tracer injection ( Figure S4B ), which may reflect impaired CNS delivery of the tracer in Tg mice due to degenerative changes (see Figures S4C-S4L for details), and thereafter this became almost equivalent between the two genotypes ( Figure S4B ). Meanwhile, persistent retention of the signals in the brain stem and spinal cord ROIs of PS19 mice was observed beyond 240 min (Figures 4B and S4B) . A more quantitative index comparable among different mice was determined by calculating the target-tofrontal-cortex ratio of fluorescence intensity and was shown to increase over time particularly in PS19 mice (Figures 4C and 4D) . This ratio was significantly greater in PS19 mice than in WT mice at 240 min ( Figure 4E ), beyond which the difference between the two lines of mice became nearly constant ( Figures  4C and 4D ). The intensity ratio of the spinal cord ROI to the frontal cortex in PS19 mice at 240 min was also significantly correlated with the abundance of NFTs stained with FSB ( Figure 4F ), but such correlations were not statistically significant in the brain stem ( Figure 4F ), implying limitations of the intensitometry in some brain regions below the cerebellum and fourth ventricle.
Intravital Imaging of Individual Tau Inclusions by PBB3
and Two-Photon Laser Scanning Fluorescence Microscopy Two-photon excitation microscopy, which enables optical sectioning, potentially up to 1 mm deep, in living tissues, could be utilized to visually demonstrate transfer of a fluorescent probe from the plasma compartment into the cytoplasm of CNS neurons and binding of the probe to intraneuronal tau inclusions. We therefore captured fluorescence signals from intravenously administered PBB3 by in vivo two-photon laser scanning microscopic imaging of the spinal cord of laminectomized PS19 mice. Within 3 s of PBB3 injection, green fluorescence signals emerged in blood vessels prelabeled with red with intraperitoneal treatment using sulforhodamine 101 and subsequently diffused from the vasculatures to the spinal cord parenchyma over the next few minutes ( Figures 5A-5F ). These diffuse signals declined thereafter due to the clearance of PBB3 from the tissue, whereas intense labeling of putative tau inclusions with green fluorescence appeared in a subpopulation of large cells morphologically identified as neurons at 3-5 min after PBB3 injection (Figures 5G and 5H) . These intracellular PBB3 fluorescent signals were not found in the spinal cord of WT mice ( Figure 5I ). As the BBB of the brain and spinal cord are presumed to be identical, the two-photon microscopic data obtained here provide compelling evidence that PBB3 rapidly transits the BBB and neuronal plasma membranes, where it binds to intraneuronal tau inclusions. Accumulation of injected PBB3 in AT8-positive, NFT-like lesions of Tg mice was postmortemly confirmed by ex vivo microscopy ( Figures 5J and 5K ).
Autoradiographic and PET Imaging of Tau Lesions in PS19 Mice by Radiolabeled PBBs
We investigated the kinetic properties of PBBs by high-performance liquid chromatography (HPLC) analyses of plasma and brain samples collected from non-Tg WT mice treated with these ligands. Following intravenous administration, PBB5 was rapidly converted into a major metabolite, which at 5 min was found at high levels in both plasma and brain extracts. Subsequent liquid chromatography-mass spectrometry (LC-MS) assays suggested that the major metabolite was likely a reduced, electrically neutralized derivative of PBB5 (Figures S5A and S5B) . Besides transventricular uptake of unmetabolized PBB5 as implied above, this uncharged form incapable of emitting nearinfrared light could readily penetrate the BBB, as well as cell membranes, and thereafter could be reoxidized into its original form, thereby enabling it to bind to tau fibrils, particularly at sites exposed to oxidative stress in pathological conditions. In addition, PBB4 was promptly converted to metabolites capable of entering the brain. Finally, studies of PBB2 and PBB3 showed that they exhibited reasonable biostability and sufficient entry into and clearance from the brain. Indeed, HPLC assays demonstrated that fractions of unmetabolized PBB2 and PBB3 in mouse plasma were 23.5% and 16.3%, respectively, at 3 min after intravenous administration and were 4.6% and 2.8%, respectively, at 30 min. There were also no metabolites of PBB2 and PBB3 detectable in the mouse brain at 3 and 30 min.
We then radiolabeled PBB2 and PBB3 with 11 C to conduct autoradiographic and PET assays using PS19 mice. In vitro autoradiography using frozen tissue sections showed binding of these radioligands to the brain stem of PS19 mice and neocortex of AD patients ( Figure 6A ). As expected from their lipophilicities, rapidly crossed the BBB and unbound and nonspecifically bound tracers were promptly washed out from the brain with a half-life of $10 min (left panel in Figure 6E ). The retention of [ 11 C]PBB3 signals in the brain stem of 12-month-old PS19 mice lasted over the imaging time (90 min), producing a pronounced difference from that in age-matched non-Tg WT mice (left panel in Figure 6E ). By selecting the striatum as a reference region lacking tau deposits, the target-to-reference ratio was estimated for the brain stem, with the value in PS19 mice peaking at around 70 min, contrasting with its continuous decrease over 60 min in WT mice (right panel in Figure 6E ). The mean ratio at 45-90 min was increased by 40% in 12-month-old PS19 mice as compared with age-matched WT mice (p < 0.01 by t test).
The agreement between localizations of PET signals and tau inclusions in PS19 mice was proven by postmortem FSB staining of brain sections from scanned mice ( Figure 6D ). Significantly, the mean target-to-reference ratio in the brain stem quantified by PET correlated closely with the number of FSB-positive inclusions per brain section in the same region of the postmortem sample (p < 0.001 by t test; data not shown). [ 11 C]PBB2 exhibited slower clearance from the brain and higher nonspecific retention in myelin-rich regions than [ 11 C]PBB3 ( Figure S6G ), resulting in insufficient contrast of tau-bound tracers in the brain stem of PS19 mice and a small difference in the target-to-reference ratio of radioactivities between PS19 and WT mice (8% at 45-90 min; p < 0.05 by t test; Figure S6H ) relative to those achieved with [ 11 C]PBB3. As radiolabeling at the dimethylamino group in PBB5 with 11 C was unsuccessful, 11 C-methylation of a hydroxyl derivative of this compound was performed, leading to the production Notably, the hippocampus of many PS19 mice was devoid of overt [ 11 C]PBB3 retention ( Figure 6C ), although a pronounced hippocampal atrophy was noted in these animals. This finding is in agreement with the well-known neuropathological features of PS19 mice in the hippocampus, because the accumulation of AT8-positive phosphorylated tau inclusions results in the degeneration of the affected hippocampal neurons prior to or immediately after NFT formation, followed by the clearance of their preNFTs or NFTs that are externalized into the interstitial CNS compartment ( Figure S2 ). To explore the feasibility of our imaging agents in studies with other tauopathy model mice, we also performed fluorescence labeling with PBBs for brain sections generated from rTg4510 mice (Santacruz et al., 2005 ; the Supplemental Experimental Procedures). As reported elsewhere (Santacruz et al., 2005) , these mice developed numerous thioflavin-S-positive neuronal tau inclusions in the neocortex and hippocampus, and reactivity of these lesions with PBBs was demonstrated by in vitro and ex vivo fluorescence imaging ( Figure S7 ). A notable difference in labeling between these two radioligands was observed in the CA1 sector and subiculum of the AD hippocampus, where fibrillar tau aggregates predominantly localized to NFTs and neuropil threads ( Figure 7A) .
We subsequently conducted an exploratory clinical PET study for patients with probable AD (n = 3) and age-matched cognitively normal control (NC) subjects (n = 3). All AD patients exhibited a marked increase in the retention of [
11 C]PIB in plaque-rich areas, and all NC were negative for this PET assay. These subjects then received a Figures 7B, 8, and 9B ). Time courses of regional radioactivity (Figures 9C and 9D; Figures S8A and S8B ) and the standardized uptake value ratio (SUVR) to the cerebellum ( Figures S8C and S8D ) demonstrated accumulation of [ 11 C]PBB3 in several brain regions of AD patients as compared to controls (definition of these VOIs is indicated in Figure S8E ). In agreement with autoradiographic findings, binding of [ 11 C]PBB3 to the medial temporal region, including the hippocampus, contrasted strikingly with the lowlevel retention of [ 11 C]PIB in this area ( Figure 7B ). There was a slight increase in the retention of [ 11 C]PBB3 primarily in the medial temporal region of a control subject with a loss of several points in Mini-Mental State Examination (MMSE) (subject 3 in Figure 8 ), appearing similar to the tau pathology at Braak stage III/IV or earlier (Braak and Braak, 1991) , distinct from the lack of enhanced [ 11 C]PIB signals. Indeed, mild increase of medial temporal SUVR ( Figure 9E ) contrasted with unremarkable change in lateral temporal and frontal SUVRs in this subject (Figures 9G and 9H) . Signals of [ 11 C]PBB3 were also intense mainly in the limbic region of a subject with early AD (subject 4 in Figure 8 ), but profound and moderate increases of SUVRs were also observed in the lateral temporal and frontal cortices, respectively, of this case ( Figures 9G and 9H ), resembling the localization of tau deposits at Braak stage V/VI (Braak and Braak, 1991) . With the further cognitive decline as scored by MMSE (subjects 5 and 6 in Figure 8 ), additional increase in the retention of [ 11 C]PBB3 was found in the medial temporal region, precuneus, and frontal cortex ( Figures 9E, 9F , and 9H). Meanwhile, a substantial decline of [ 11 C]PBB3 binding was noted in the lateral temporal cortex of subject 6 (Figures 8 and 9G ). The SUVRs in the medial temporal region, precuneus, and frontal cortex were consequently well correlated with the decline of MMSE scores ( Figures 9E, 9F , and 9H). In distinction with [ 11 C]PBB3-PET data, there was no overt association between the binding of [ 11 C]PIB and disease severity in AD patients (Figure 8 ), consistent with previous observations. These data support the potential utility of [ 11 C]PBB3 for clarifying correlations between the distribution of tau deposition and the symptomatic progression of AD.
As in vitro fluorescence staining indicated that PBB3 was reactive with not only tau lesions but also several types of senile plaques, particularly dense core plaques, density of binding sites, and affinity of [ 11 C]PBB3 for these sites were quantified by autoradiographic binding assays with hippocampal and neocortical sections of AD brains enriched with NFTs and senile plaques, respectively. These analyses demonstrated that specific radioligand binding sites were primarily constituted by high-affinity, low-capacity binding components in NFT-rich regions and low-affinity, high-capacity binding components in plaque-rich regions ( Figures S9A and S9B) . A subsequent simulation for radioligand binding in an area containing these two types of binding sites at a ratio of 1:1 indicated that the selectivity of [ 11 C]PBB3 for NFTs versus plaques may be inversely associated with concentration of free radioligands (Figure S9C) . In a range of free concentration in the brain achievable See also Figure S9 . gray matter of AD patients, by conducting autoradiography and FSB histochemistry for the same sections. Radiolabeling associated with dense cored plaques accounted for less than 1% and 3% of total gray matter signals in the temporal cortex and precuneus, respectively ( Figures S9D-S9H Figure 9I ), providing evidence for in vivo detection of tau lesions in plaque-negative tauopathies. Interestingly, right-side dominant [
11 C]PBB3-PET signals in the basal ganglia were consistent with laterality of atrophy in this area ( Figure S8F ). These findings may also be associated with a right-side dominant decrease in cerebral blood flow and left-side dominant motor signs in this patient.
DISCUSSION
Here, we report our efforts to develop BBB-penetrant ligands that are capable of binding to and visualizing intracellular tau aggregates in AD and non-AD tauopathies. These compounds may accordingly be useful for the differential diagnosis of neurological conditions in elderly subjects on the basis of the distribution of tau lesions, thereby opening up novel avenues for research in elucidating mechanisms of tau-mediated neurodegeneration, as well as tau-focused biomarkers and therapies.
Despite numerous efforts to develop imaging ligands to visualize tau pathologies in the brains of patients with AD and related tauopathies, the urgent need for these tau biomarkers remains largely unmet. To address this significant challenge, we also took advantage of a multimodal imaging system, which facilitates a quick and label-free validation of candidate compounds in terms of their transfer to the brain and retention in tau-rich regions. In addition, subcellular-resolution imaging optics exemplified by two-photon laser scanning microscopy provided proof of the rapid transfer of intravenously administered potential tau pathology imaging agents from plasma to the CNS extracellular matrix and subsequently to the cytoplasm of neurons, where they can bind to intracellular tau inclusions. Based on these encouraging preliminary data using nonlabeled compounds, a subset of these compounds was radiolabeled for use in PET imaging of Tg mice that model tau pathology, and a radioligand that yielded the best visualization of tau lesions in these Tg mice was selected for further testing in human AD patients and NC subjects as well as patients with probable CBD. This stepwise strategy enabled us to identify and advance the most promising PET probe for the visualization and quantitative assessment of tau pathology in the CNS of living human subjects. Interestingly, another research group has recently reported development of 18 F-labeled PET ligands for tau lesions mostly through assessments of binding to brain tissues, but not recombinant tau assemblies (Zhang et al., 2012; Chien et al., 2013) , as in the present approach. These radioligands have been implied to produce considerably high contrasts for tau pathologies in living AD brains, and relatively long radioactive half-life of 18 F would enable delivery of radioligands from a radiosynthesis sites to multiple PET facilities. [
11 C]PBB3 has distinct advantages over these compounds, as exemplified by affinity for diverse tau lesions, including Tg mouse tau aggregates, applicability to multimodal imaging, and induction of smaller radioactive exposure than 18 F-labeled ligands. In the present work, we clinically validated the performance of (Braak and Braak, 1991) , thereby resembling localization of senile plaques, except for the predominance of tau aggregates in the hippocampal formation. This rationalizes the use of radioactivity in the medial temporal area as an index to validate an imaging probe for tau pathology versus Ab deposits in AD patients from prodromal to advanced stages. Furthermore, our preliminary data suggest that [ 11 C]PBB3 may be capable of capturing the temporospatial spreading of neurofibrillary tau pathologies from the limbic system (Braak stage III/IV or earlier) to neocortical areas (Braak stage V/VI) with the progression of AD (Figure 8) . A considerable subset of tau lesions at Braak stage I/II is composed of phosphorylated tau deposits barely reactive with thioflavin-S (i.e., pretangles), and NFTs are relatively low in number and are confined to the transentorhinal cortex (Braak and Braak, 1991; Braak et al., 2011) . Therefore, detection of these early tau pathologies would be more difficult. Our nextstage clinical study with expanded sample size and wider range of MMSE scores is currently ongoing to pursue tau accumulation in normal controls and subjects with mild cognitive impairments and AD at diverse stages and will bring more compelling insights into the significance of tau PET imaging in early diagnosis and prediction of AD. In addition, alterations of [ 11 C]PBB3 retention were indicated in the transition from mild to moderate AD.
Loss of PET signals in the lateral temporal cortex of a patient with moderate AD (subject 6 in Figure 8 ) might not result from atrophy of this region, as the hippocampus of the same subject exhibited strong [ 11 C]PBB3 binding despite marked atrophy. Possible explanations for this change include formation of extracellular NFTs and their envelopment by astrocytes in the degenerating neocortex, profoundly modifying accessibility of these NFTs to exogenous molecules (Schmidt et al., 1988) . This notion would need to be examined by combined autoradiogarphic and immunohistochemical assays of different brain regions.
Being able to visualize tau deposits with [ 11 C]PBB3 in non-AD tauopathies, such as PSP, CBD, and related disorders, is also of major importance, as suggested in the present PET data the support detectability of tau deposition in living CBD brains. As compared with NFTs and neuropil threads in AD, abundant tau deposits are largely confined to specific neuroanatomical locations of the CNS in tau-positive, plaque-negative illnesses, as exemplified by PSP and CBD (Dickson et al., 2011) , but the homogenous and low-level background signals of [11C]PBB3 in brain parenchyma indicate the possibility of detecting tau lesions in these disorders. Following such in vivo assessments, a postmortem neuropathological evaluation of scanned subjects would be required as a reference standard for PET assays of non-AD tau pathologies.
[ 11 C]PIB-positive plaque formation nearly plateaus prior to the progression of brain atrophy in AD (Engler et al., 2006) C]PBB3 retention in the hippocampus of PS19 mice. In the hippocampal formation of AD patients, neurons bearing NFTs that resemble those in the PS19 hippocampus may drive neurodegeneration similar to that observed in either the PS19 hippocampus or brain stem, and this issue could be addressed in future studies using [ 11 C]PBB3-PET and MRI in diverse mouse models, including PS19 and rTg4510 mice, and human subjects.
Our analyses of multiple b sheet ligands illustrated electrochemical and/or conformational diversities of b-pleated sheets among amyloid aggregates, producing a selectivity of these compounds for a certain spectrum of fibrillar pathologies (Figures 1 and S1 ). Lipophilicities of the b sheet ligands could determine their reactivity with noncored plaques, as noted among the PBBs studied here (Figure 1 ), although the molecular properties underlying this variation are yet to be elucidated. Meanwhile, we noted that all b sheet ligands tested in the present study were reactive with dense core plaques regardless of their lipophilicities. This may affect in vivo PET signals, particularly in AD brain areas with abundant cored plaques, such as the precuneus. However, our combined autoradiographic and histochemical assessments indicated that [
11 C]PBB3 bound to dense core plaques accounts for less than 10% of total specific radioligand binding in these areas, and this percentage in fact includes binding to tau fibrils in plaque neurites in addition to Ab amyloid core. A second possibility to account for the diversity of ligand reactivity to tau lesions may arise from the packing distance between two juxtaposed b sheets in tau filaments and is discussed in the Supplemental Discussion. Possible mechanisms that underlie this property are discussed in the Supplemental Discussion. The present work has also implied the potential utility of multimodal imaging systems for translational development of therapeutic agents that counteract tau fibrillogenesis. Optical imaging with a near-infrared fluorescent probe, such as PBB5, could provide the least invasive technique to assess tau accumulation in living mouse models. As demonstrated by our in vitro and ex vivo fluorescence labeling, all PBBs share a similarity in terms of their reactivity with tau aggregates. Hence, PBB5 optics may be applicable to early screening of therapeutic agents that suppress tau deposition, and the data on abundance of tau lesions obtained by this approach may be translatable to advanced stages of assessments using [
11 C]PBB3-PET in animal models and humans. By contrast, pharmacokinetic properties of PBB5 ( Figure S5 ) were found to be distinct from those of electrically neutral PBBs, including PBB2 and PBB3. These considerations would be of importance in developing and using fluorescent ligands applicable to optical and PET imaging.
To conclude, our class of multimodal imaging agents offers the possibility of visual investigations of fibrillary tau pathologies at subcellular, cellular, and regional levels. These assay systems are potentially powerful tools for the longitudinal evaluation of anti-tau treatments (Marx, 2007) , as a single probe may facilitate a seamless, bidirectional translation between preclinical and clinical insights. PET tracers would also serve a more immediate therapeutic purpose by enabling the assessment of the effects of antiAb and anti-tau therapies on tau pathologies in living AD patients.
EXPERIMENTAL PROCEDURES
Compounds and Reagents PBB1 (Wako Pure Chemical Industries), PBB2 (ABX), PBB3 (Nard Institute), PBB4 (ABX), mPBB5 (Nard Institute), desmethyl precursor of [ buta-1,3-dienyl]-3-ethyl-6-hydroxybenzothiazol-3-ium; Nard Institute), and 2-[8-(4-dimethylaminophenyl)octa-1,3,5,7-tetraenyl]-3-ethylbenzothiazol-3-ium (DM-POTEB; Nard Institute) were custom synthesized. Information on other chemicals is provided in the Supplemental Experimental Procedures. ClogP for each compound was calculated using ACD Chemsketch logP software (Advanced Chemistry Development).
Animal Models
Tg mice heterozygous for human T34 (4-repeat tau isoform with 1 N-terminal insert) with FTDP-17 P301S mutation driven by mouse prion protein promoter, also referred to as PS19 mice (Yoshiyama et al., 2007) , were bred and kept on a C57BL/6 background. All mice studied here were maintained and handled in accordance with the National Research Council's Guide for the Care and Use of Laboratory Animals and our institutional guidelines. Protocols for the present animal experiments were approved by the Animal Ethics Committees of the National Institute of Radiological Sciences.
Postmortem Brain Tissues
Procedures for preparation of human and mouse brain sections are given in the Supplemental Experimental Procedures.
In Vitro and Ex Vivo Fluorescence Microscopy
Six micrometer paraffin sections generated from patient brains and 20 mm frozen sections of mouse brains were stained with 10 À3 % b sheet ligands dissolved in 50% ethanol for 1 hr at room temperature. Images of the fluorescence signals from these compounds were captured by nonlaser (BZ-9000; Keyence Japan) and confocal laser scanning (FV-1000; Olympus) microscopes. In the confocal imaging, excitation/emission wavelengths (nm) were optimized for each compound as follows: 405/420-520 (PBB3, FSB, PIB, BF-227, BF-158, FDDNP, thioflavin-S), 488/520-580 (PBB2, PBB4), 515/ 530-630 (PBB1, curcumin), and 635/645-720 (PBB5, BF-189, DM-POTEB). Subsequently, the tested samples and adjacent sections probed serially with each ligand were autoclaved for antigen retrieval, immunostained with the anti-tau monoclonal antibody AT8 that is specific for tau phosphorylated at Ser 202 and Thr 205 (Endogen), as well as a polyclonal antibody against AbN3(pE), and inspected using the microscopes noted above. For ex vivo imaging, PS19 and non-Tg WT at 10-12 months of age were anesthetized with 1.5% (v/v) isoflurane and were given 1 mg/kg PBB1-4, 0.1 mg/kg PBB5, or 10 mg/kg FSB by syringe via tail vein. The animals were killed by decapitation at 60 min after tracer administration. Brain and spinal cord were harvested and cut into 10-mm-thick sections on a cryostat (HM560). The sections were imaged using microscopes as in the in vitro assays and were labeled with either FSB or AT8, followed by microscopic re-examination.
Ex Vivo and In Vivo Multiphoton Imaging
Experimental procedures are given in the Supplemental Experimental Procedures.
In Vivo and Ex Vivo Pulsed Laser Scanning Imaging
Noninvasive scans of isoflurane-anesthetized non-Tg WT and tau Tg mice at 12 months of age were performed using a small animal-dedicated optical imager (eXplore Optix; ART). Scan protocols are given in the Supplemental Experimental Procedures.
Radiosynthesis of [
11 C]PBB2 Experimental procedures are given in the Supplemental Experimental Procedures.
11 C]PBB3 [ 11 C]Methyl iodide was produced and transferred into 300 ml of dimethyl sulphoxide (DMSO) containing 1.5-2 mg of tert-butyldimethylsilyl desmethyl precursor and 10 mg of potassium hydroxide at room temperature. The reaction mixture was heated to 125 C and maintained for 5 min. After cooling the reaction vessel, 5 mg of tetra-n-butylammonium fluoride hydrate in 600 ml of water was added to the mixture to delete the protecting group, and then 500 ml of HPLC solvent was added to the reaction vessel. The radioactive mixture was transferred into a reservoir for HPLC purification (CAPCELL PAK C 18 column, 10 3 250 mm; acetonitrile/50 mM ammonium formate = 4/6, 6 ml/min). The fraction corresponding to [ 11 C]PBB3 was collected in a flask containing 100 ml of 25% ascorbic acid solution and 75 ml of Tween 80 in 300 ml of ethanol and was evaporated to dryness under a vacuum. The residue was dissolved in 10 ml of saline (pH 7.4) to obtain [ 11 C]PBB3 (970-1,990 GBq at the end of synthesis [EOS] ) as an injectable solution. The final formulated product was radiochemically pure (R95%) as detected by analytic HPLC (CAPCELL PAK C 18 column, 4.6 3 250 mm; acetonitrile/50 mM ammonium formate = 4/6, 2 ml/min). The specific activity of [ 11 C]PBB3 at EOS was 37-121 GBq/mmol, and [
11 C]PBB3 maintained its radioactive purity exceeding 90% over 3 hr after formulation.
11 C]mPBB5 Experimental procedures are given as Supplemental Experimental Procedures.
11 C]PIB Radiolabeling of PIB was performed as described elsewhere (Maeda et al., 2011) . The specific activity of [ 11 C]PIB at EOS was 50-110 GBq/mmol.
In Vitro and Ex Vivo Autoradiography
In Vivo PET Imaging of Mice PET scans were performed using a microPET 80/20, 80/20, 40/60, and 40/60 at 0, 6, 7, 8, 9 , and 15 min, respectively; flow rate, 6 ml/min) as described elsewhere (Suzuki et al., 1999) . The radiotracer injection and following scans and plasma assays were conducted in a dimly lit condition to avoid photoracemization of the chemicals. Individual MRI data were coregistered to the PET images using PMOD software (PMOD Technologies). Volumes of interest (VOIs) were drawn on coregistered MR images and were transferred to the PET images. Procedures of image analyses are provided in the Supplemental Experimental Procedures.
We additionally carried out PET scans of a patient who was clinically diagnosed as having corticobasal syndrome, as described in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
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